高雄市生物科技發展協會|http://www.khba.org.tw
會員登入
記住帳號 自動登入
會員名錄
各式辦法
下載專區
留言板
您目前的位置:首頁 / 活動與新訊
Novartis $2 million gene therapy for rare disorder is world's most expensive drug
活動日期:2019.05.27
2019.05.27  

Novartis $2 million gene therapy for rare disorder is world's most expensive drug
https://finance.yahoo.com/news/novartis-2-million-gene-therapy-233948617.html
 

 

FILE PHOTO: Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann/File Photo

By John Miller and Caroline Humer
ZURICH/NEW YORK, (Reuters) - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
The Food and Drug Administration approved Zolgensma for children under the age of two with SMA, including those not yet showing symptoms. The approval covers babies with the deadliest form of the inherited disease as well as those with types where debilitating symptoms may set in later.
"This is potentially a new standard of care for babies with the most serious form of SMA," said Dr. Emmanuelle Tiongson, a pediatric neurologist at Children's Hospital Los Angeles who has provided Zolgensma to patients under an expanded access programme. "The job now is trying to negotiate with insurers that this would be a long-term savings."
Novartis executives defended the price, saying that a one-time treatment is more valuable than expensive long-term treatments that cost several hundred thousand dollars a year.
Novartis touched off a debate over what gene therapy is worth last year, estimating its treatment would be cost-effective at up to $5 million per patient. A review in April by an independent U.S. group, the Institute for Clinical and Economic Review (ICER), concluded Novartis' value estimate for Zolgensma was excessive.
But on Friday, ICER said that based on Novartis' additional clinical data, the broad FDA label and its launch price, it believed that the drug fell within the upper bound of its range for cost-effectiveness.
Novartis said it was offering health insurers the option of installment payments for Zolgensma as well as refunds if the treatment does not work and upfront discounts for payers who commit to standardized coverage terms.
Novartis Chief Executive Vas Narasimhan has much riding on Zolgensma, describing it as a near cure for SMA if delivered soon after birth. But data proving its durability extends to only about five years. The therapy uses a virus to provide a normal copy of the SMN1 gene to babies born with a defective gene. It is delivered by infusion.


A RIVAL TO BIOGEN
Novartis is expecting European and Japanese approval later this year. Zolgensma will compete with Biogen Inc's Spinraza, the first approved treatment for SMA.
The disease often leads to paralysis, breathing difficulty and death within months for babies born with the most serious Type I form. SMA affects about one in every 10,000 live births, with 50 percent to 70 percent having Type I disease.
Spinraza, approved in late 2016, requires infusion into the spinal canal every four months. Its list price of $750,000 for the initial year and $375,000 annually thereafter was also deemed excessive by ICER.
Some neurologists see gene therapy becoming the preferred treatment for newborns with severe SMA, while acknowledging that families may choose to wait for long-term safety and efficacy data for Zolgensma. Novartis is looking into whether the death of one severely ill baby treated with Zolgensma was related to the therapy.
"Most families will want to do the gene therapy since it avoids the frequent spinal taps," said Dr. Russell Butterfield of the University of Utah in Salt Lake City. Butterfield has received payments from Biogen for consulting.
The FDA said it approved Zolgensma based on clinical trials involving 36 patients aged 2 weeks to 8 months. The agency said patients treated with Zolgensma showed significant improvement in developmental motor milestones such as head control and ability to sit up.
The most common side effects of Zolgensma are elevated liver enzymes and vomiting. The FDA is requiring Zolgensma's label to include a warning that acute serious liver injury can occur.


With additional studies underway, Novartis said it has so far treated more than 150 patients with Zolgensma, which was acquired with its $8.7 billion purchase of AveXis last year.
Wall Street analysts have forecast sales of $2 billion by 2022, according to a Refinitiv survey. Spinraza sales hit $1.7 billion last year, and are seen rising to $2.2 billion in 2022. Roche is developing risdiplam, an oral drug, for the condition and plans to file for approval later this year.

共有310筆資料 頁數: 第3頁(共16頁)
編號 標題 新增日期
1 You Are When You Eat 2023.12.06
2 六旬健康長者 尿道感染大腸桿菌 菌血入侵心臟 竟爆發類重度心.. 2023.12.06
3 Statins may reduce breast cancer mortality rates 2023.11.29
4 默克藥廠在台擴大投資 成立製藥頂級實驗室培訓高端人才 2023.11.29
5 Study links lifestyle choices and gender to severity of fa.. 2023.11.28
6 Base editing, a new form of gene therapy, sharply lowers b.. 2023.11.24
7 AI for drug discovery is booming, but who owns the patents? 2023.11.22
8 Unlocking the Secrets of Bacterial Transcription 2023.11.15
9 美生醫公司編輯基因降低膽固醇 預計2025年啟動2期實驗 2023.11.15
10 New nanocapsule treatment boosts immune response against s.. 2023.11.01
11 Walking and Mediterranean diet may be the ticket to reduci.. 2023.10.18
12 The Vaginal Microbiome is Finally Getting Recognized 2023.10.11
13 奈米藥物治療年輕癌症患者的效果較差且可能產生終生副作用!! .. 2023.10.11
14 Epigenetic Marks May Cause Brain Tumor Formation 2023.10.03
15 Glycogen Metabolism May Play a Key Role in Pulmonary Fibro.. 2023.09.27
16 COVID boosters are back: what scientists say about whether.. 2023.09.19
17 Journey to the Center of the Ear 2023.09.13
18 A Bacterial Culprit for Rheumatoid Arthritis 2023.09.05
19 Pet Hamsters Spread SARS-CoV-2 in Hong Kong: Preprint 2022.02.08
20 What We Learned About COVID-19 in 2021 2022.01.11
上一頁  1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16  下一頁
版權所有©2006 高雄市生物科技發展協會 所有文字、資料禁止轉用
地址:高雄市中正一路120號14樓之3 TEL:(07)591-9569 / FAX:(07)591-9018 / e-mail: khba.tw@gmail.com
累積進站人數:2896915